Prof. Peter Schmid, Consultant Medical Oncologist
Prof. Peter Schmid
Consultant Medical Oncologist
Prof. Peter Schmid MD PhD FRCP
Consultant Medical Oncologist
Prof. Peter Schmid
Consultant Medical Oncologist MD PhD FRCP
Prof. Schmid is a recommended Consultant Medical Oncologist
Areas of expertise
- Breast oncology
- Dealing with early breast lumps
- Lung cancer
- Immunotherapy
- Triple negative breast cancer
Recommendations for Prof. Schmid
These recommendations are for information purposes only. Doctors providing recommendations do so in good faith and are not responsible for clinical outcomes.
Recommended by:
byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon
❝Prof. Peter Schmid is an expert medical oncologist with a particular interest in clinical trials and immunotherapy for some of the most aggressive types of triple-negative breast cancer. He is key member of our multi-disciplinary team at the London Breast Institute.❞
byMr Neill Patani, Consultant Oncoplastic & Reconstructive Breast Surgeon
❝Prof. Peter Schmid is an expert medical oncologist with a particular interest in clinical trials and immunotherapy for some of the most aggressive types of triple-negative breast cancer. He is key member of our multi-disciplinary team at the London Breast Institute.❞
Make an appointment
Address
-
LOC at Chelsea
102 Sydney Street, Chelsea, London, SW3 6NJ
-
LOC - Leaders in Oncology Care
95-97 Harley Street, London, W1G 6AF
-
London Bridge Hospital
27 Tooley Street, London, SE1 2PR
-
The Wellington Hospital
Wellington Place, St John's Wood, London, NW8 9LE
About Prof. Peter Schmid
GMC number: 6111181
Year qualified: 1997
Place of primary qualification: Technische Universität München
Areas of expertise
- Breast oncology
- Dealing with early breast lumps
- Lung cancer
- Immunotherapy
- Triple negative breast cancer
Professional memberships
Articles by Prof. Peter Schmid
C45the role of ribociclib in hormone receptor-positive (hr+), human epidermal growth factor receptor 2-negative (her2–) early breast cancer: the earlee adjuvant clinical trials program
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (fergi): a randomised, double-blind, placebo-controlled, phase 2 trial
Systematic review of the impact of breast-conserving surgery on cancer outcomes of multiple ipsilateral breast cancers
Phlda1 mediates drug resistance in receptor tyrosine kinase-driven cancer
